For the Inventor, By the Inventor

Enter assignee name

Boston, MA, United States of America

Valo Health, Inc.

USPTO Granted Patents = 33

EPO Patents = 3

Trademarks = 9

Forward Citations = 27

Loading Chart...

Loading Chart...

70 inventors (with patents filed for the assignee):

Xiaozhang Zheng (20 out of 114 patents)

Pui Yee Ng (18 out of 79 patents)

Bingsong Han (16 out of 77 patents)

4. David R Lancia, Jr (16 out of 114 patents)

5. Aleksandra Rudnitskaya (13 out of 53 patents)

6. Jennifer R Thomason (11 out of 46 patents)

7. Mary-Margaret Zablocki (11 out of 48 patents)

8. Cuixian Liu (11 out of 56 patents)

9. Kenneth W Bair (10 out of 82 patents)

10. Matthew W Martin (10 out of 74 patents)

11. Zhongguo Wang (7 out of 58 patents)

12. Alexandre Joseph Buckmelter (7 out of 54 patents)

13. Stephanos Ioannidis (6 out of 40 patents)

14. Justin Andrew Caravella (5 out of 48 patents)

15. Nicholas Barczak (5 out of 15 patents)

Core Competencies:

HDAC Inhibitors

NAMPT

GPR120 Modulators

Ubiquitin-Specific Protease

Isoquinolinones

Hydroxamic Acids

Bicyclic Compounds

Carboxamides

Pyrrolo Compounds

Thienopyrazine

Amido Derivatives

Piperidine

33 patents: Sort by Forward Citations

1. 12612382 - Process for preparing 6-substituted-1-(2H)-isoquinolinones and intermediate compound (2026-04-28),

2. 12595449 - Integrated system for 3D tissue culture (2026-04-07),

3. 12590087 - Inhibiting USP36 (2026-03-31),

4. 12479807 - METHODS USING HDAC11 INHIBITORS (2025-11-25),

5. 12336981 - Compounds and compositions for the inhibition of NAMPT (2025-06-24),

6. 12304904 - Bicyclic [4,6,0] hydroxamic acids as HDAC inhibitors (2025-05-20),

7. 12264137 - 3-aryl-4-amido-bicyclic [4,5,0] hydroxamic acids as HDAC inhibitors (2025-04-01),

8. 12252490 - Inhibiting deubiquitinase USP25 and USP28 (2025-03-18),

9. 12213969 - 2-spiro-5- and 6-hydroxamic acid indanes as HDAC inhibitors (2025-02-04),

10. 12162888 - Carboxamides as ubiquitin-specific protease inhibitors (2024-12-10),

11. 12116362 - Monocyclic compounds useful as GPR120 modulators (2024-10-15),

12. 12018030 - Pyrrolo and pyrazolopyrimidines as ubiquitin-specific protease 7 inhibitors (2024-06-25),

13. 11919891 - Bicyclic compounds useful as GPR120 modulators (2024-03-05),

14. 11919839 - Alpha-cinnamide compounds and compositions as HDAC8 inhibitors (2024-03-05),

15. 11891365 - 3-alkyl-4-amido-bicyclic [4,5,0] hydroxamic acids as HDAC inhibitors (2024-02-06),

Company Overview

Valo Health, Inc. is a biotechnology company based in Boston, MA, specializing in the integration of artificial intelligence and machine learning with drug discovery and development. The organization focuses on creating innovative therapies by leveraging advanced computational models to understand complex biological systems. Valo Health aims to streamline the drug development process, enhancing efficiency and effectiveness in bringing new treatments to market, ultimately improving patient outcomes across various therapeutic areas.

Profile summary synthesized from public USPTO records and patent filings.

Company Badge

USPTO Data Jan 1 1976 - Oct 20 2026

33 Patents

#74 in Boston, MA

#619 in Massachusetts

#10,309 in US

#20,162 in the World

Boston, MA, United States of America

Valo Health, Inc.

Forward Citations = 27

70 inventors:

Xiaozhang Zheng (20 out of 114 patents)

Pui Yee Ng (18 out of 79 patents)

Bingsong Han (16 out of 77 patents)

4. David R Lancia, Jr (16 out of 114 patents)

5. Aleksandra Rudnitskaya (13 out of 53 patents)

IDiyas Innovation Intelligence. (2026). Company Patent Portfolio: Valo Health, Inc.. Retrieved from https://idiyas.com/company/valo-health

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]

Loading…